Combining genetics, blood, urine, and stool data to predict complications of metabolic syndrome
Validating Integrative Multi-omics Approaches in Metabolic Syndrome-related Diseases: A Step Towards Precision Medicine
The team will try combining genetic, blood, urine, and stool data to see if patterns predict complications in adults with or without metabolic syndrome.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 6266 (estimated) |
| Ages | 20 Years and up |
| Sex | All |
| Sponsor | Chang Gung Memorial Hospital Academic / other |
| Locations | 1 site (Taoyuan) |
| Trial ID | NCT07248371 on ClinicalTrials.gov |
What this trial studies
This longitudinal, multi-center observational project will enroll adults with metabolic syndrome and age- and sex-matched controls from Chang Gung Memorial Hospitals. Researchers will collect annual blood samples plus urine and stool to generate genomics, transcriptomics, metabolomics, and microbiome profiles and link these to clinical records from the hospital research database. Advanced bioinformatics, dimensionality reduction, clustering, and machine-learning feature selection will be used to integrate the datasets and build models of disease progression and complications. The goal is to identify multi-layer molecular networks and signatures that differentiate patients who develop complications from those who do not.
Who should consider this trial
Good fit: Adults aged 20 years or older who can give informed consent, including people who meet diagnostic criteria for metabolic syndrome and age- and sex-matched individuals without metabolic syndrome, are eligible.
Not a fit: Pregnant or breastfeeding people, patients on dialysis for end-stage renal disease, those receiving active cancer treatment, organ transplant recipients, or individuals with dementia are excluded and would not benefit from participation in this observational protocol.
Why it matters
Potential benefit: If successful, this work could enable earlier, more personalized prevention and treatment by identifying molecular signatures that predict who will develop metabolic complications.
How similar studies have performed: Prior multi-omics research has produced promising biomarker signals for metabolic conditions but few approaches have yet produced broadly validated clinical prediction tools, so this is a promising but still-emerging area.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Individuals (male or female) aged 20 years or older * Willing and able to provide written informed consent to participate in the study Exclusion Criteria: * Pregnant or breastfeeding women * Patients with end-stage renal disease receiving hemodialysis or peritoneal dialysis * Individuals currently undergoing active cancer treatment * Recipients of any organ transplantation * Patients diagnosed with dementia
Where this trial is running
Taoyuan
- Chang Gung Memorial Hospitals, Linkou — Taoyuan, Taiwan (Recruiting)
Study contacts
- Study coordinator: Chi-Hsiao Yeh, MD PhD
- Email: yehccl@cgmh.org.tw
- Phone: +886-3-3281200
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.